Phospho-MAP3K7 (S439) Antibody

What is MAP3K7 and why is phosphorylation at S439 significant?

MAP3K7, also known as TAK1 (Transforming growth factor-beta-activated kinase 1), is a mitogen-activated protein kinase kinase kinase that plays crucial roles in multiple signaling pathways. MAP3K7 is encoded by the MAP3K7 gene with UniProt ID O43318 and functions as a key upstream regulator in cellular processes .

Phosphorylation at Serine 439 (S439) represents a specific post-translational modification that affects MAP3K7 function. Research has demonstrated that phosphorylation at this site is regulated by both kinases and phosphatases, including PP2C phosphatases . The S439 phosphorylation site appears to play a regulatory role in MAP3K7 signaling pathways, particularly in response to growth factor stimulation and stress conditions.

Recent phosphoproteomic investigations have identified S439 as a site that shows significant regulation in response to phosphatase inhibition, particularly PP2C inhibitors, suggesting its importance in cellular signaling networks .

How is Phospho-MAP3K7 (S439) involved in cellular signaling pathways?

MAP3K7/TAK1 functions as an upstream kinase in multiple signaling cascades, including:

• MAPK signaling pathways, where it can activate p38 MAPK and JNK pathways

• NF-κB signaling pathway, which regulates inflammatory responses

• TGF-β signaling, which controls cell growth, differentiation, and apoptosis

Phosphorylation at S439 has been specifically observed to change in response to vasopressin treatment in renal epithelia , suggesting a role in kidney function. Additionally, phosphoproteomics data indicate that S439 phosphorylation is regulated in response to EGF (Epidermal Growth Factor) stimulation .

Research has also demonstrated connections between MAP3K7 and mTOR signaling. Studies have shown that silencing MAP3K7 reduces the phosphorylation of mTOR, and there is a correlation between MAP3K7 and mTOR expression in hepatocellular carcinoma (HCC) .

What are the key characteristics of Phospho-MAP3K7 (S439) antibodies?

Phospho-MAP3K7 (S439) antibodies are typically:

• Host: Predominantly rabbit-derived polyclonal antibodies

• Specificity: Detect endogenous levels of MAP3K7 only when phosphorylated at Ser439

• Reactivity: Human, mouse, and rat species

• Applications: Western blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), and ELISA

• Recommended dilutions:

  • WB: 1:500-1:2000

  • IHC: 1:100-1:300

  • ELISA: 1:5000-1:10000

Most commercially available antibodies are produced using synthetic phosphorylated peptides corresponding to residues surrounding S439 in human MAP3K7 (typically amino acids 411-460) .

How should researchers optimize Western blot conditions for Phospho-MAP3K7 (S439) detection?

For optimal Western blot detection of Phospho-MAP3K7 (S439):

• Sample preparation:

  • Use phosphatase inhibitors in lysis buffers to preserve phosphorylation status

  • Load 50μg of total protein per lane for cell lysates

  • Ensure complete denaturation of samples

• Electrophoresis and transfer:

  • Look for the target band at approximately 67-75 kDa (calculated MW: 67 kDa, observed MW: 75 kDa)

  • Use standard SDS-PAGE (8-10% gels) and wet transfer protocols

• Antibody incubation:

  • Primary antibody dilution: Start with 1:500-1:1000 and optimize if needed

  • Incubate overnight at 4°C for optimal results

  • Use appropriate HRP-conjugated secondary antibodies (typically anti-rabbit IgG)

• Controls:

  • Include positive controls such as EGF-stimulated cell lysates

  • Consider using phosphatase-treated samples as negative controls

  • Total MAP3K7 antibodies should be used in parallel to normalize for total protein expression

The molecular weight observed on Western blots (75 kDa) may differ from the calculated molecular weight (67 kDa) due to post-translational modifications .

What are the recommended protocols for Cell-Based ELISA using Phospho-MAP3K7 (S439) antibodies?

For Cell-Based ELISA techniques using Phospho-MAP3K7 (S439) antibodies:

• Cell preparation:

  • Grow cells in 96-well microplates

  • Apply treatments of interest (e.g., EGF stimulation, phosphatase inhibitors)

  • Fix cells with appropriate fixative (typically 4% paraformaldehyde)

• Antibody incubation:

  • Block with provided blocking buffer

  • Dilute Phospho-MAP3K7 (S439) antibody at approximately 1:5000 for ELISA applications

  • Incubate with HRP-conjugated secondary antibody

• Detection and normalization:

  • Use colorimetric substrate for HRP activity measurement

  • Perform cell staining with crystal violet for cell number normalization

  • Calculate the relative phosphorylation level by normalizing to cell number

This approach offers advantages over traditional Western blot analysis:

• More quantitative results

• Higher throughput (96-well format)

• Conservation of cell culture and treatment reagents

• Faster results availability for analysis

How can researchers validate the specificity of Phospho-MAP3K7 (S439) antibody signals?

To validate the specificity of Phospho-MAP3K7 (S439) antibody signals:

• Phosphatase treatment control:

  • Treat duplicate samples with lambda phosphatase to remove phosphorylation

  • Signal should disappear in phosphatase-treated samples

• RNA interference:

  • Use siRNA or shRNA against MAP3K7 to knockdown expression

  • Both phospho-specific and total protein signals should decrease

  • Research has confirmed decreased phosphorylation in MAP3K7-silenced cells

• Phosphorylation site mutants:

  • Express wild-type and S439A mutant (non-phosphorylatable) constructs

  • The antibody should not detect the S439A mutant

• Peptide competition:

  • Pre-incubate the antibody with phospho-peptide immunogen

  • This should block specific binding and eliminate the signal

  • Some companies offer blocking peptides for this purpose

• Stimulus-dependent phosphorylation:

  • Verify that phosphorylation increases with appropriate stimuli

  • For example, EGF stimulation or PP2C inhibitor treatment should affect S439 phosphorylation

These validation steps should be documented to ensure the reliability of experimental results when using Phospho-MAP3K7 (S439) antibodies.

How does Phospho-MAP3K7 (S439) regulation intersect with mTOR signaling in cancer biology?

Research has revealed important connections between MAP3K7 and mTOR signaling in cancer, particularly in hepatocellular carcinoma (HCC):

These findings suggest that targeting the MAP3K7-mTOR signaling axis might represent a potential therapeutic approach for HCC treatment, and phosphorylation status at sites like S439 could serve as biomarkers for pathway activation.

What is the relationship between EGF signaling, phosphatases, and MAP3K7 (S439) phosphorylation?

Recent phosphoproteomic investigations have revealed intricate relationships between EGF signaling, phosphatases, and MAP3K7 (S439) phosphorylation:

• EGF-dependent phosphorylation dynamics:

  • EGF stimulation triggers complex phosphorylation cascades

  • Phosphoproteomic studies have identified thousands of regulated phosphosites, including those on MAP3K7

• Phosphatase regulation:

  • PP2C phosphatase inhibition leads to up-regulation of S439 on MAP3K7/TAK1

  • This is in contrast to SHP2 inhibition, which tends to cause down-regulation of many phosphosites

  • These opposing trends suggest differential regulation of phosphorylation networks by distinct phosphatases

• Integration with MAPK pathways:

  • MAP3K7 functions as an upstream MAPK kinase kinase of p38α

  • PP2C is known to directly target MAP3K7

  • The regulation of S439 phosphorylation may influence downstream MAPK signaling events

This complex interplay highlights the importance of understanding phosphorylation dynamics in signal transduction networks and suggests that therapeutic targeting of specific phosphatases might allow for precise modulation of MAP3K7 activity.

How do genetic mutations in MAP3K7 relate to phosphorylation status and disease phenotypes?

Mutations in the MAP3K7 gene have been linked to distinct clinical disorders with different underlying molecular mechanisms:

• Disease-associated mutations:

  • Frontometaphyseal dysplasia type 2 (FMD2)

  • Cardiospondylocarpofacial syndrome (CSCF)

  • These disorders show distinct phenotypes despite being caused by mutations in the same gene

• Genotype-phenotype correlations:

  • CSCF-causing mutations appear to have a loss-of-function effect

  • FMD2-causing mutations have different functional consequences

  • This suggests that different mutations affect MAP3K7 activity in distinct ways

• Impact on phosphorylation:

  • While not directly studied, disease-causing mutations might affect:

    • Kinase activity of MAP3K7

    • Accessibility of phosphorylation sites including S439

    • Interactions with regulatory partners

    • Response to upstream signals

Understanding how disease-causing mutations affect MAP3K7 phosphorylation status at sites like S439 represents an important research direction that could illuminate the molecular basis of these disorders and potentially guide therapeutic approaches.

What are common technical challenges when detecting Phospho-MAP3K7 (S439) and how can they be addressed?

Researchers frequently encounter several technical challenges when working with Phospho-MAP3K7 (S439) antibodies:

• Low signal intensity:

  • Cause: Insufficient phosphorylation, rapid dephosphorylation during sample preparation

  • Solution: Include phosphatase inhibitors in lysis buffers; enrich for phosphoproteins; use stimuli known to increase S439 phosphorylation; optimize antibody concentration

• Multiple bands or background:

  • Cause: Non-specific binding, cross-reactivity with similar phosphorylation motifs

  • Solution: Increase blocking time/concentration; optimize antibody dilution; perform peptide competition controls; use phospho-null mutants as negative controls

• Variability between experiments:

  • Cause: Inconsistent cell culture conditions, variable phosphorylation states

  • Solution: Standardize cell densities and treatment protocols; include positive controls in each experiment; normalize phospho-signal to total protein

• Differences between applications:

  • Cause: Different antibody performance in various applications (WB vs. IHC vs. ELISA)

  • Solution: Validate antibody in each specific application; optimize protocols for each technique; consider using application-specific antibody formulations

• Isoform detection:

  • Cause: MAP3K7 has multiple isoforms due to alternative splicing

  • Solution: Verify which isoforms contain the S439 site; use isoform-specific controls; consult antibody documentation for isoform specificity

How can researchers quantitatively analyze changes in MAP3K7 (S439) phosphorylation under different experimental conditions?

For quantitative analysis of MAP3K7 (S439) phosphorylation:

• Western blot densitometry:

  • Normalize phospho-signal to total MAP3K7 expression

  • Use housekeeping proteins (GAPDH) as loading controls

  • Employ imaging software for accurate band quantification

  • Present results as fold-change relative to control conditions

• Cell-based ELISA approaches:

  • Calculate the ratio of phospho-MAP3K7 to total cellular protein

  • Normalize using crystal violet staining for cell number

  • Determine relative phosphorylation changes across treatment conditions

• Phosphoproteomics:

  • Use label-free quantitation (LFQ) to measure phosphopeptide intensity

  • Filter phosphosites based on valid quantitation values (≥70% per condition)

  • Normalize and impute missing values using standard methods

  • Compare fold-changes and statistical significance between conditions

• Data representation:

  • Use volcano plots to display log2 fold-change differences (x-axis) and significance values (y-axis)

  • Present heatmaps to visualize patterns across multiple conditions or phosphosites

  • Include principal component analysis (PCA) to identify major sources of variation in the data

This quantitative analysis allows researchers to determine the significance of changes in MAP3K7 phosphorylation and relate these changes to biological outcomes.

What protocols should be followed when using Phospho-MAP3K7 (S439) antibodies for immunohistochemistry in tissue samples?

For optimal immunohistochemistry (IHC) results with Phospho-MAP3K7 (S439) antibodies:

• Tissue preparation:

  • Fix tissues in 10% neutral buffered formalin or other appropriate fixative

  • Embed in paraffin and section at 4-5μm thickness

  • Mount on positively charged slides

• Antigen retrieval:

  • Critical for phospho-epitopes which are often masked by fixation

  • Use citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Heat-induced epitope retrieval via microwave, pressure cooker, or water bath

• Antibody protocol:

  • Block endogenous peroxidase activity with hydrogen peroxide

  • Apply protein blocking solution to reduce background

  • Dilute Phospho-MAP3K7 (S439) antibody at 1:100-1:300

  • Incubate overnight at 4°C in a humidified chamber

• Detection and visualization:

  • Use appropriate secondary antibody system (typically HRP-polymer based)

  • Develop with DAB (3,3'-diaminobenzidine) chromogen

  • Counterstain with hematoxylin

  • Dehydrate, clear, and mount with permanent mounting medium

• Controls and validation:

  • Include positive control tissues (tissues known to express phosphorylated MAP3K7)

  • Include negative controls (primary antibody omitted)

  • Consider phosphatase-treated section controls to verify phospho-specificity

These procedures should be optimized for specific tissue types and research questions to ensure reliable and reproducible results when studying phosphorylated MAP3K7 in tissue contexts.

What are emerging research directions for studying MAP3K7 (S439) phosphorylation in disease contexts?

Several promising research directions are emerging for studying MAP3K7 (S439) phosphorylation:

• Cancer biology:

  • Further exploration of the MAP3K7-mTOR axis in various cancer types beyond HCC

  • Investigation of S439 phosphorylation as a potential biomarker for cancer progression

  • Development of therapeutic approaches targeting MAP3K7 phosphorylation status

• Genetic disorders:

  • Examination of how disease-causing mutations in MAP3K7 affect S439 phosphorylation

  • Investigation of phosphorylation-dependent signaling in FMD2 and CSCF pathogenesis

  • Development of mutation-specific interventions based on phosphorylation profiles

• Drug development:

  • Screening for compounds that specifically modulate S439 phosphorylation

  • Development of phosphatase inhibitors targeting enzymes that regulate MAP3K7

  • Creation of therapeutic antibodies that recognize specific phosphorylation states

• Systems biology:

  • Integration of phosphoproteomics data to understand MAP3K7 regulation in signaling networks

  • Computational modeling of phosphorylation dynamics under various stimuli

  • Multi-omics approaches to connect phosphorylation changes with transcriptional and metabolic outcomes

These research directions hold promise for translating our understanding of MAP3K7 (S439) phosphorylation into clinically relevant applications.

How can researchers integrate phosphoproteomics and functional genomics approaches to study MAP3K7 (S439) regulation?

Integration of phosphoproteomics with functional genomics offers powerful approaches to study MAP3K7 (S439) regulation:

• Comprehensive phosphosite mapping:

  • Use mass spectrometry-based phosphoproteomics to identify all phosphorylation sites on MAP3K7

  • Quantify changes in S439 phosphorylation relative to other sites

  • Determine kinetics of phosphorylation/dephosphorylation following stimuli

• CRISPR-based functional screens:

  • Perform CRISPR knockout or activation screens to identify regulators of S439 phosphorylation

  • Generate S439A (non-phosphorylatable) and S439D/E (phosphomimetic) mutants

  • Assess phenotypic consequences of altering S439 phosphorylation status

• Integrative data analysis:

  • Combine phosphoproteomics data with transcriptomics to identify downstream effects

  • Apply pathway enrichment analysis to contextualize S439 phosphorylation

  • Use machine learning approaches to predict regulatory relationships

• Temporal and spatial regulation:

  • Employ live-cell imaging with phospho-specific biosensors

  • Track S439 phosphorylation dynamics in response to stimuli in real-time

  • Determine subcellular localization of phosphorylated MAP3K7